BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 30685931)

  • 1. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach.
    Mousa HS; Carbone M; Malinverno F; Ronca V; Gershwin ME; Invernizzi P
    Autoimmun Rev; 2016 Sep; 15(9):870-6. PubMed ID: 27393766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Status of Liver Transplantation for Primary Biliary Cholangitis.
    Aguilar MT; Carey EJ
    Clin Liver Dis; 2018 Aug; 22(3):613-624. PubMed ID: 30259857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PRIMARY BILIARY CHOLANGITIS: THERAPEUTIC APPROACH IN THE MODERN ERA].
    Abu Backer F; Abu Mouch S; Mari A
    Harefuah; 2018 Dec; 157(12):791-796. PubMed ID: 30582314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
    Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
    Olsson R
    Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward precision medicine in primary biliary cholangitis.
    Carbone M; Ronca V; Bruno S; Invernizzi P; Mells GF
    Dig Liver Dis; 2016 Aug; 48(8):843-50. PubMed ID: 27324985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.